| Developers: | Bristol-Myers Squibb |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2022: Bristol-Myers Squibb destroys cancer drugs for clinical research in Russia
As it became known on July 11, 2022, Bristol-Myers Squibb, in connection with the withdrawal from the Russian market, decided to withdraw nivolumab from local clinics.
With a complaint about the actions of the American manufacturer, the Association of Cancer Patients "Hello" appealed to the European Coalition of Cancer Patients (ECPC). The public organization "Cancer is curable" sent a request to intervene in the situation to the Ministry of Health of the Russian Federation. The leader of the movement, Olga Badson-Chernyak, in a letter indicates that patients have lost treatment with the latest drugs and in some cases were left "without a chance of any therapy to continue their lives," Kommersant reports.
According to Irina Borovova, the facts of seizure of drugs are confirmed by employees of the N.N. Blokhin National Medical Research Center of Oncology and N.N. Petrov National Medical Research Center of Oncology. The press service of the N.N. Petrov National Medical Research Center of Oncology told Medvestnik that they had received instructions from the company to destroy all drugs intended for clinical trials. They clarified that the issue of transferring patients who participated in the trials to standard therapy is now being resolved.
According to Svetlana Zavidova, director of the Association of Clinical Research Organizations, it may not reach the real seizure and destruction of nivolumab, since BMS left Russia and is unlikely to monitor the fulfillment of its condition. Polina Gabay, vice president of the Together Against Cancer Cancer Organizations Support Fund, noted that medical organizations have no choice. According to her, the drugs were supplied for clinical trials and can only be used for these purposes. Companies, including BMS, are recalling drugs and have the right to destroy them or resend them, she said.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |